Massachusetts — May 6, 2026 — Leads & Copy — Insulet Corporation (NASDAQ: PODD) has announced its financial results for the first quarter of 2026, which ended March 31. The company reported revenue of $761.7 million, a 33.9% increase (30.1% in constant currency) and exceeding the high end of its guidance range.
Total Omnipod revenue reached $758.4 million, marking a 36.9% increase (33.0% in constant currency). U.S. Omnipod revenue grew by 28.3% to $515.6 million, while international Omnipod revenue increased by 59.4% (45.2% in constant currency) to $242.9 million. Drug Delivery revenue totaled $3.3 million.
Operating income was $122.1 million, representing 16.0% of revenue, a 40 basis point increase year-over-year. Adjusted operating income was $133.5 million, or 17.5% of revenue, up 110 basis points from the previous year. Net income reached $91.1 million, or $1.30 per diluted share, compared to $35.4 million, or $0.50 per diluted share, in the prior year. Adjusted net income was $99.8 million, or $1.42 per diluted share, an increase of 35.4% and 39.7%, respectively.
Insulet highlighted several strategic achievements, including the launch of Omnipod 5 and Omnipod Discover™ in five Middle Eastern countries, expanding Omnipod 5 availability to 19 countries. Data on the new Omnipod 5 algorithm update was presented at the Advanced Technologies & Treatments for Diabetes (ATTD) International Conference, following a successful limited market release. The updated algorithm offers improved automation and performance, featuring a new 100 mg/dL target glucose setting for greater personalization.
The company also completed a U.S. limited market release of the Omnipod 5 algorithm with FreeStyle Libre 3 Plus, broadening sensor connectivity across CGM platforms. Milestones were achieved in the development of a fully closed-loop automated insulin delivery (AID) system for adults with type 2 diabetes, including data from the EVOLUTION 2 trial presented at ATTD, showing a 68% time in range with no boluses. The first participant was enrolled in the EVOLVE pivotal study to support a 510(k) filing in 2027.
Insulet repurchased 1.25 million shares of common stock and advanced its sustainability efforts, as detailed in the 2025 Sustainability Report.
President and CEO Ashley McEvoy stated that the company had a strong start to the year, delivering continued growth momentum and robust operating margin expansion. The company is raising its total company revenue growth outlook to reflect its progress.
Insulet provided revenue guidance for the second quarter and full year 2026. For Q2 2026, the company expects total revenue growth of 20% – 22% in constant currency. For FY 2026, total revenue growth is projected at 21% – 23% in constant currency.
Insulet will host a conference call on May 6, 2026, at 8:00 a.m. Eastern Time to discuss the financial results and outlook. A live webcast will be available on the Investor Relations section of the company’s website.
Insulet Corporation is a medical device company focused on simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections or fingersticks.
For more information, visit insulet.com or omnipod.com.
Source: Insulet Corporation
